13F Filings History of GUARDIAN LIFE INSURANCE CO OF AMERICA

Latest 13F report
Q4 2025 - 10 Feb 2026
Signature - Title
John H. Walter - Senior Vice President, Chief Financial Officer
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by GUARDIAN LIFE INSURANCE CO OF AMERICA. Form 13F is required to be filed within 45 days of the end of a calendar quarter. GUARDIAN LIFE INSURANCE CO OF AMERICA reported 1 stock holding with total value $199,370 as of Q1 2024. Park Avenue Institutional Advisers LLC is reporting for GUARDIAN LIFE INSURANCE CO OF AMERICA.

Notify me when GUARDIAN LIFE INSURANCE CO OF AMERICA files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value

Park Avenue Institutional Advisers LLC is reporting for GUARDIAN LIFE INSURANCE CO OF AMERICA:

Name Holdings Value Location File Number
Park Avenue Institutional Advisers LLC $1,005,869 New York, NY 028-16979
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 $0 13F-NT 10 Feb 2026, 14:57
Q3 2025 $0 13F-NT 30 Oct 2025, 15:37
Q2 2025 $0 13F-NT 31 Jul 2025, 15:25
Q1 2025 $0 13F-NT 06 May 2025, 15:49
Q4 2024 $0 13F-NT 07 Feb 2025, 09:03
Q3 2024 $0 13F-NT 04 Nov 2024, 14:42
Q2 2024 $0 13F-NT 05 Aug 2024, 10:56
Q1 2024 1 $199,370 $0 $0 $0 COIN 13F-HR 07 May 2024, 14:15
Q4 2023 0 $0 13F-NT 02 Feb 2024, 09:37
Q3 2023 0 $0 13F-NT 02 Nov 2023, 11:03
Q2 2023 0 $0 13F-NT 09 Aug 2023, 12:00
Q1 2023 0 $0 13F-NT 12 May 2023, 10:35
Q4 2022 0 $0 13F-NT 14 Feb 2023, 07:52
Q3 2022 0 $0 13F-NT 01 Nov 2022, 13:55
Q2 2022 0 $0 13F-NT 05 Aug 2022, 08:10
Q1 2022 0 $0 13F-NT 12 May 2022, 11:04
Q4 2021 0 $0 13F-NT 10 Feb 2022, 09:57
Q3 2021 3 $209,796,000 +$209,796,000 $0 +$209,796,000 LQD, DKNG, OLO Restatement 16 Nov 2021, 14:59
Q2 2021 0 $0 $0 -$202,228,000 -$202,228,000 13F-HR 13 Aug 2021, 13:40
Q1 2021 1 $202,228,000 $0 $0 $0 LQD 13F-HR 14 May 2021, 15:01
Q4 2020 1 $214,792,000 +$214,792,000 $0 +$214,792,000 LQD 13F-HR 12 Feb 2021, 10:59
Q3 2020 0 $0 $0 $0 $0 13F-HR 13 Nov 2020, 11:58
Q2 2020 0 $0 $0 $0 $0 13F-HR 31 Jul 2020, 08:56
Q1 2020 0 $0 $0 -$422,608,000 -$422,608,000 13F-HR 14 May 2020, 10:13
Q4 2019 514 $422,608,000 +$69,512,489 -$344,426,614 -$274,914,125 IWF, EFA, IWN, IWS, EEM 13F-HR 11 Feb 2020, 12:16
Q3 2019 528 $668,379,000 +$11,645,053 -$68,807,061 -$57,162,008 IWD, LQD, GLD, EFA, IWN 13F-HR 12 Nov 2019, 11:11
Q2 2019 529 $724,527,000 +$17,137,536 -$101,732,204 -$84,594,668 IWD, LQD, GLD, EFA, HYG 13F-HR 12 Aug 2019, 16:48
Q1 2019 528 $787,635,000 +$223,173,031 -$72,454,402 +$150,718,629 LQD, IWD, EFA, GLD, HYG 13F-HR 14 May 2019, 15:30
Q4 2018 525 $578,886,000 +$101,804,050 -$61,922,714 +$39,881,336 IWD, GLD, SPY, EFA, IWS 13F-HR 06 Feb 2019, 15:12
Q3 2018 522 $612,602,000 +$16,792,205 -$639,006 +$16,153,199 IWD, GLD, EFA, IWN, IWS 13F-HR 14 Nov 2018, 10:44
Q2 2018 521 $590,825,000 +$140,968,518 -$89,703,829 +$51,264,689 IWD, GLD, EFA, IWN, IWS 13F-HR 10 Aug 2018, 06:10
Q1 2018 521 $541,953,000 +$139,446,694 -$51,893,175 +$87,553,519 IWD, GLD, EFA, IAU, DBA 13F-HR 10 May 2018, 14:24
Q4 2017 525 $457,313,000 +$66,968,871 -$271,407,000 -$204,438,129 IWD, GLD, DBA, IWM, IWR 13F-HR 14 Feb 2018, 12:05
Q3 2017 521 $649,761,000 +$500,340,897 -$13,747,316 +$486,593,581 HYG, LQD, IWD, GLD, DBA 13F-HR 14 Nov 2017, 12:01
Q2 2017 513 $136,886,000 +$6,927,100 -$540,515,130 -$533,588,030 GLD, SLV, FIT, AR, UNG 13F-HR 14 Aug 2017, 15:46
Q1 2017 526 $691,943,000 +$194,620,640 -$192,796,956 +$1,823,684 LQD, HYG, GLD, DBA, IWR 13F-HR 12 May 2017, 13:37
Q4 2016 536 $677,081,000 +$44,684,347 -$438,980,775 -$394,296,428 HYG, LQD, IWR, IWM, EFA 13F-HR 14 Feb 2017, 14:09
Q3 2016 565 $1,088,272,000 +$98,531,367 -$338,410,698 -$239,879,331 HYG, LQD, IWR, EFA, IWM 13F-HR 14 Nov 2016, 12:13
Q2 2016 585 $1,268,812,000 +$198,267,623 -$81,960,810 +$116,306,813 HYG, LQD, IWR, GLD, EFA 13F-HR 15 Aug 2016, 12:48
Q1 2016 581 $1,138,184,000 +$324,996,736 -$167,984,589 +$157,012,147 HYG, IWR, EFA, IWM, GILEAD SCIENCES INC 13F-HR 12 May 2016, 16:06
Q4 2015 575 $990,148,000 +$121,373,337 -$141,986,980 -$20,613,643 HYG, IWR, IWM, GILEAD SCIENCES INC, GLD Restatement 12 Feb 2016, 11:30
Q3 2015 577 $984,150,000 +$147,695,341 -$131,841,813 +$15,853,528 SPY, IWR, IWM, GLD, GILEAD SCIENCES INC 13F-HR 12 Nov 2015, 17:15
Q2 2015 575 $1,031,485,000 +$104,725,487 -$122,255,012 -$17,529,525 IWM, IWR, GILEAD SCIENCES INC, GLD, DBA Restatement 14 Aug 2015, 15:42
Q1 2015 581 $1,056,383,000 +$247,795,406 -$176,130,584 +$71,664,822 IWM, IWR, GILEAD SCIENCES INC, DBA, MYLAN LABORATORIES 13F-HR 05 May 2015, 16:08
Q4 2014 580 $982,958,000 +$170,959,475 -$156,917,362 +$14,042,113 DBA, GILEAD SCIENCES INC, EEM, PRICELINECOM INC, MYLAN LABORATORIES 13F-HR 12 Feb 2015, 15:22
Q3 2014 576 $983,036,000 +$118,022,109 -$149,164,761 -$31,142,652 DBA, GILEAD SCIENCES INC, PRICELINECOM INC, GLD, DBE 13F-HR 06 Nov 2014, 16:32
Q2 2014 570 $1,040,187,000 +$112,257,730 -$221,448,176 -$109,190,446 DBA, IWM, EFA, GILEAD SCIENCES INC, GLD 13F-HR 13 Aug 2014, 14:32
Q1 2014 580 $1,125,701,000 +$72,019,263 -$76,170,812 -$4,151,549 DBA, IWM, GILEAD SCIENCES INC, THE PRICELINE GROUP INC, GLD 13F-HR 14 May 2014, 13:40
Q4 2013 581 $1,091,831,000 $0 $0 $0 DBA, IWM, GILEAD SCIENCES INC, PRICELINECOM INC, GLD 13F-HR 11 Feb 2014, 16:21